New pill targets Tough-to-Treat lung cancer mutation
Disease control
Not yet recruiting
This study is testing a new oral medication called BPI-361175 for adults with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called an EGFR mutation, including a hard-to-treat type known as C797S. The main goals are to find a safe and effective dos…
Phase: PHASE1, PHASE2 • Sponsor: Xcovery Holdings, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC